{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:56:56Z","timestamp":1780059416363,"version":"3.54.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00277-024-05800-1","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T01:02:03Z","timestamp":1715821323000},"page":"3121-3133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Significance of absolute neutrophil count before allogeneic hematopoietic stem cell transplantation in adult patients with aplastic anemia"],"prefix":"10.1007","volume":"103","author":[{"given":"Yukinori","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Zaimoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Kanaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Hiramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ohigashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"5800_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjh.13853","volume":"172","author":"SB Killick","year":"2016","unstructured":"Killick SB, Bown N, Cavenagh J et al (2016) Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 172:187\u2013207. https:\/\/doi.org\/10.1111\/bjh.13853","journal-title":"Br J Haematol"},{"key":"5800_CR2","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1182\/blood-2016-08-693481","volume":"129","author":"A Bacigalupo","year":"2017","unstructured":"Bacigalupo A (2017) How I treat acquired aplastic anemia. Blood 129:1428\u20131436. https:\/\/doi.org\/10.1182\/blood-2016-08-693481","journal-title":"Blood"},{"key":"5800_CR3","doi-asserted-by":"publisher","first-page":"100772","DOI":"10.1016\/j.blre.2020.100772","volume":"47","author":"R Iftikhar","year":"2021","unstructured":"Iftikhar R, Chaudhry QUN, Anwer F et al (2021) Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies. Blood Rev 47:100772. https:\/\/doi.org\/10.1016\/j.blre.2020.100772","journal-title":"Blood Rev"},{"key":"5800_CR4","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1365-2141.2008.07450.x","volume":"144","author":"P Scheinberg","year":"2009","unstructured":"Scheinberg P, Wu CO, Nunez O, Young NS (2009) Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol 144:206\u2013216. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07450.x","journal-title":"Br J Haematol"},{"key":"5800_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1600-0609.2009.01378.x","volume":"84","author":"MH Chang","year":"2010","unstructured":"Chang MH, Kim KH, Kim HS et al (2010) Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia. Eur J Haematol 84:154\u2013159. https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01378.x","journal-title":"Eur J Haematol"},{"key":"5800_CR6","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00277-015-2348-5","volume":"94","author":"X Zhao","year":"2015","unstructured":"Zhao X, Zhang L, Jing L et al (2015) The role of paroxysmal nocturnal hemoglobinuria clones in response to immunosuppressive therapy of patients with severe aplastic anemia. Ann Hematol 94:1105\u20131110. https:\/\/doi.org\/10.1007\/s00277-015-2348-5","journal-title":"Ann Hematol"},{"key":"5800_CR7","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","volume":"376","author":"DM Townsley","year":"2017","unstructured":"Townsley DM, Scheinberg P, Winkler T et al (2017) Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med 376:1540\u20131550. https:\/\/doi.org\/10.1056\/NEJMoa1613878","journal-title":"N Engl J Med"},{"key":"5800_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2109965","volume":"386","author":"R Peffault de Latour","year":"2022","unstructured":"Peffault de Latour R, Kulasekararaj A, Iacobelli S et al (2022) Eltrombopag added to immunosuppression in severe aplastic anemia. N Engl J Med 386:11\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2109965","journal-title":"N Engl J Med"},{"key":"5800_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3324\/haematol.2021.278413","volume":"107","author":"Y Zaimoku","year":"2022","unstructured":"Zaimoku Y, Patel BA, Shalhoub R et al (2022) Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag. Haematologica 107:126\u2013133. https:\/\/doi.org\/10.3324\/haematol.2021.278413","journal-title":"Haematologica"},{"key":"5800_CR10","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00277-013-1984-x","volume":"93","author":"H Yagasaki","year":"2014","unstructured":"Yagasaki H, Shichino H, Ohara A et al (2014) Immunosuppressive therapy with horse anti-thymocyte globulin and cyclosporine as treatment for fulminant aplastic anemia in children. Ann Hematol 93:747\u2013752. https:\/\/doi.org\/10.1007\/s00277-013-1984-x","journal-title":"Ann Hematol"},{"key":"5800_CR11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1080\/16078454.2019.1631424","volume":"24","author":"J Liu","year":"2019","unstructured":"Liu J, Lu XY, Cheng L et al (2019) Clinical outcomes of immunosuppressive therapy for severe aplastic anemia patients with absolute neutrophil count of zero. Hematology 24:492\u2013497. https:\/\/doi.org\/10.1080\/16078454.2019.1631424","journal-title":"Hematology"},{"key":"5800_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.11406\/rinketsu.59.64","volume":"59","author":"K Nishiwaki","year":"2018","unstructured":"Nishiwaki K, Sano K, Kamiyama Y et al (2018) [Reduced-intensity umbilical cord blood transplantation for adult patients with fulminant aplastic anemia]. Rinsho Ketsueki 59:64\u201368. https:\/\/doi.org\/10.11406\/rinketsu.59.64","journal-title":"Rinsho Ketsueki"},{"key":"5800_CR13","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.11406\/rinketsu.61.1464","volume":"61","author":"K Makishima","year":"2020","unstructured":"Makishima K, Obara N, Sakamoto T et al (2020) [Haploidentical transplantation from a related donor as first-line treatment for fulminant aplastic anemia]. Rinsho Ketsueki 61:1464\u20131468. https:\/\/doi.org\/10.11406\/rinketsu.61.1464","journal-title":"Rinsho Ketsueki"},{"key":"5800_CR14","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00277-023-05256-9","volume":"102","author":"LQ Wu","year":"2023","unstructured":"Wu LQ, Huang LF, Yang H et al (2023) Comparison of haploidentical-allogeneic hematopoietic stem cell transplantation and intensive immunosuppressive therapy for patients with severe aplastic anemia with an absolute neutrophil count of zero: a retrospective study. Ann Hematol 102:2015\u20132023. https:\/\/doi.org\/10.1007\/s00277-023-05256-9","journal-title":"Ann Hematol"},{"key":"5800_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","volume":"103","author":"Y Atsuta","year":"2016","unstructured":"Atsuta Y (2016) Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol 103:3\u201310. https:\/\/doi.org\/10.1007\/s12185-015-1894-x","journal-title":"Int J Hematol"},{"key":"5800_CR16","unstructured":"Przepiorka D, Weisdorf D, Martin P et al (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplantat 15(6):825\u2013828"},{"key":"5800_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL et al (1980) Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69:204\u2013217. https:\/\/doi.org\/10.1016\/0002-9343(80)90380-0","journal-title":"Am J Med"},{"key":"5800_CR18","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"SG Holtan","year":"2015","unstructured":"Holtan SG, DeFor TE, Lazaryan A et al (2015) Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 125:1333\u20131338. https:\/\/doi.org\/10.1182\/blood-2014-10-609032","journal-title":"Blood"},{"key":"5800_CR19","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912\u20132919. https:\/\/doi.org\/10.1182\/blood-2005-05-2004","journal-title":"Blood"},{"key":"5800_CR20","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis 46:1813\u20131821. https:\/\/doi.org\/10.1086\/588660","journal-title":"Clin Infect Dis"},{"key":"5800_CR21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18:695\u2013706. https:\/\/doi.org\/10.1002\/(sici)1097-0258(19990330)18:6%3C695::aid-sim60%3E3.0.co;2-o","journal-title":"Stat Med"},{"key":"5800_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software EZR for medical statistics. Bone Marrow Transpl 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transpl"},{"key":"5800_CR23","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1182\/blood-2006-10-052308","volume":"109","author":"RE Champlin","year":"2007","unstructured":"Champlin RE, Perez WS, Passweg JR et al (2007) Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 109:4582\u20134585. https:\/\/doi.org\/10.1182\/blood-2006-10-052308","journal-title":"Blood"},{"key":"5800_CR24","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3324\/haematol.2011.054841","volume":"97","author":"A Bacigalupo","year":"2012","unstructured":"Bacigalupo A, Soci\u00e9 G, Schrezenmeier H et al (2012) Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica 97:1142\u20131148. https:\/\/doi.org\/10.3324\/haematol.2011.054841","journal-title":"Haematologica"},{"key":"5800_CR25","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.bbmt.2016.01.012","volume":"22","author":"R Kumar","year":"2016","unstructured":"Kumar R, Kimura F, Ahn KW et al (2016) Comparing outcomes with bone marrow or peripheral blood stem cells as graft source for matched sibling transplants in severe aplastic anemia across different economic regions. Biol Blood Marrow Transpl 22:932\u2013940. https:\/\/doi.org\/10.1016\/j.bbmt.2016.01.012","journal-title":"Biol Blood Marrow Transpl"},{"key":"5800_CR26","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1016\/j.bbmt.2016.07.002","volume":"22","author":"Y Kuwatsuka","year":"2016","unstructured":"Kuwatsuka Y, Kanda J, Yamazaki H et al (2016) A comparison of outcomes for cord blood transplantation and unrelated bone marrow transplantation in adult aplastic anemia. Biol Blood Marrow Transpl 22:1836\u20131843. https:\/\/doi.org\/10.1016\/j.bbmt.2016.07.002","journal-title":"Biol Blood Marrow Transpl"},{"key":"5800_CR27","doi-asserted-by":"publisher","unstructured":"Onishi Y, Mori T, Yamazaki H et al (2023) Comparison of Haploidentical Stem Cell transplantation with Post-transplantation Cyclophosphamide versus umbilical cord blood transplantation in adult patients with aplastic Anemia. Transpl Cell Ther 29. https:\/\/doi.org\/10.1016\/j.jtct.2023.09.009. :766.e1-766.e8","DOI":"10.1016\/j.jtct.2023.09.009"},{"key":"5800_CR28","doi-asserted-by":"publisher","first-page":"1004787","DOI":"10.3389\/fimmu.2022.1004787","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Chen X, Yang D et al (2022) The prognostic impact of previously infectious complications on allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia: a single-center, retrospective study. Front Immunol 13:1004787. https:\/\/doi.org\/10.3389\/fimmu.2022.1004787","journal-title":"Front Immunol"},{"key":"5800_CR29","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/j.bbmt.2018.07.018","volume":"24","author":"S Xu","year":"2018","unstructured":"Xu S, Wu L, Zhang Y et al (2018) Allogeneic hematopoietic stem cell transplantation for the treatment of severe aplastic anemia patients with infection: a single-center retrospective study. Biol Blood Marrow Transpl 24:2532\u20132539. https:\/\/doi.org\/10.1016\/j.bbmt.2018.07.018","journal-title":"Biol Blood Marrow Transpl"},{"key":"5800_CR30","doi-asserted-by":"publisher","unstructured":"Liu L, Miao M, Chen X et al (2021) Outcomes of severe aplastic anemia patients with infection proceeding with allogeneic hematopoietic stem cell transplantation, versus patients without infection. Bone Marrow Transplant 56:2591\u20132594. https:\/\/doi.org\/10.1038\/s41409-021-01398-4","DOI":"10.1038\/s41409-021-01398-4"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05800-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05800-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05800-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T06:07:29Z","timestamp":1722060449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05800-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5800"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05800-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"assertion":[{"value":"27 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"M.S. is co-founder and shareholder in Celaid Therapeutics. The other authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}